Strategic Growth Precision BioLogic has expanded through acquisitions, including Affinity Biologicals in 2018 and George King Bio-Medical in 2025, creating a broader hemostasis diagnostics portfolio and access to new customer segments and distribution channels that can be leveraged for cross-selling and upsell opportunities.

Expanded Product Line The company offers CRYOcheck plasma products, chromogenic factor assays, and antibody lines, enabling unified solutions for coagulation testing. This breadth presents sales potential by bundling products for laboratories seeking end-to-end hemostasis testing capabilities.

North American Footprint Serving over 1,000 clinical laboratories with direct overnight delivery in North America indicates strong distribution efficiency and service value that can be extended to new domestic customers, clinical research sites, and hospital networks.

Regulatory and Market Readiness Recent FDA clearance for Factor VIII Deficient Plasma and ongoing updates to chromogenic assays suggest continued regulatory progress and product relevance for emerging therapies, enabling sales pitches tied to treatment innovations like novel hemophilia therapies.

Technical Synergy A tech-enabled ecosystem including MySQL, cloud services, and advertising platforms supports scalable operations and targeted marketing. This environment can be leveraged to deliver precision, data-driven outreach to coagulation labs, blood banks, and research institutions seeking compatible testing solutions.